Furthermore, it is established that the six confirmed LRRK2 pathogenic mutations all increase the kinase activity of LRRK2 (Sheng et al., 2012; Steger et al., 2016), and thus there is substantial interest in developing LRRK2 inhibitors as potential PD therapeutics (Chan and Tan, 2017; West, 2017). The gene discussed is LRRK2; the disease is Parkinson disease.